Evidence map›Paper›PMID 41951517›Full record

ArticleEBioMedicine2026

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

Cosmin A Bejan, Michelle Wang, Sriram Venkateswaran, Ewa A Bergmann, Laura Hiles, Yaomin Xu, G Scott Chandler, Sam Brondfield, Jordyn Silverstein, Francis Wright and 10 more

Abstract read
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Cosmin A BejanDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, USA. Electronic address: adi.bejan@vanderbilt.edu.
Michelle WangDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, USA; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, USA.
Sriram VenkateswaranF. Hoffmann-La Roche, Basel, Switzerland.
Ewa A BergmannF. Hoffmann-La Roche, Basel, Switzerland.
Laura HilesRoche Products Ltd, Welwyn Garden City, United Kingdom.
Yaomin XuDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, USA; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, USA.
G Scott ChandlerF. Hoffmann-La Roche, Basel, Switzerland.
Sam BrondfieldDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA.
Jordyn SilversteinDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, USA.
Francis WrightDivision of General Internal Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA.
Kimberly de DiosDiabetes Center, University of California San Francisco, San Francisco, USA; Division of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, USA.
Daniel M KimDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.
Eric MukherjeeDepartment of Dermatology, Vanderbilt University Medical Center, Nashville, USA.
Matthew S KrantzDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
Lydia YaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, USA.
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, USA.
Elizabeth J PhillipsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, USA; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, USA.
Rajat MohindraF. Hoffmann-La Roche, Basel, Switzerland.
Zoe QuandtDiabetes Center, University of California San Francisco, San Francisco, USA; Division of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, USA.

Funding

Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9M
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibitionR01CA227481 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BALKO, JUSTIN M, JOHNSON, DOUGLAS B · 2019 to 2023
$2.6M
Leveraging artificial intelligence methods and electronic health records for pediatric pharmacovigilanceR21HD113234 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BEJAN, COSMIN ADRIAN · 2023 to 2023
$481k
NCI NIH HHS R01 CA227481NHLBI NIH HHS R01 HL156021NICHD NIH HHS R21 HD113234
6 · The paper itself

Abstract

backgroundLarge language models (LLMs) have emerged as transformative technologies, revolutionising natural language understanding and generation across various domains, including medicine. In this study, we investigated the capabilities, limitations, and generalisability of Generative Pre-trained Transformer (GPT) models in analysing unstructured patient notes from large healthcare datasets to identify immune-related adverse events (irAEs) associated with the use of immune checkpoint inhibitor (ICI) therapy.

methodsWe evaluated the performance of GPT-3.5, GPT-4, and GPT-4o models on manually annotated datasets of patients receiving ICI therapy, sampled from two electronic health record (EHR) systems and seven clinical trials. A zero-shot prompt was designed to exhaustively identify irAEs at both the patient level (main analysis) and the note level (secondary analysis). The LLM-based system followed a multi-label classification approach to identify any combination of irAEs associated with individual patients or clinical notes. System evaluation was conducted for each available irAE as well as for broader categories of irAEs classified at the organ level.

findingsOur analysis included 442 patients across three institutions. The most common irAEs manually identified in the patient datasets included pneumonitis (N = 64), colitis (N = 56), rash (N = 32), and hepatitis (N = 28). The GPT models demonstrated generalisable abilities in identifying irAEs across EHRs and clinical trial reports. Overall, the models achieved relatively high sensitivity and specificity but only moderate positive predictive values, reflecting a potential bias towards overpredicting irAE outcomes. GPT-4o achieved the highest F1 and micro-averaged F1 scores for both patient-level and note-level evaluations. Highest performance was observed in the haematological (F1 range = 1.0-1.0), gastrointestinal (F1 range = 0.81-0.85), and musculoskeletal and rheumatologic (F1 range = 0.67-1.0) irAE categories. Error analysis uncovered substantial limitations of GPT models in handling textual causation, where adverse events should not only be accurately identified in clinical text but also causally linked to immune checkpoint inhibitors.

interpretationThis study demonstrated that GPT models can automate the detection of immune related adverse events in varied healthcare datasets, reducing the burden on physicians and other healthcare professionals by limiting the need for manual review. This capability will accelerate the generation of safety insights across large healthcare datasets and facilitate the characterisation of patient-level drivers of toxicities, thus enhancing safety monitoring and ultimately improving patient care.

fundingNational Institutes of Health, Roche, National Health and Medical Research Council of Australia, Stevens-Johnson Syndrome Foundation, Angela Anderson Research Fund, Larry L Hillblom Foundation and UCSF Research Allocation Program.

Indexed as

Drug-Related Side Effects and Adverse ReactionsElectronic Health RecordsImmune Checkpoint InhibitorsClinical Trials as TopicGenerative Artificial IntelligenceHumansLarge Language ModelsNatural Language ProcessingImmune Checkpoint InhibitorsClinical trialsElectronic health recordsGenerative artificial intelligenceImmune-related adverse eventsLarge language models

Identifiers

PMID41951517
PMCPMC13174231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.